Follower of Jesus ✝️, Husband and Father 👨👩👦, Kidney Doctor 🩺, Postgrad Research - Body Composition in CKD 💪🏼. 🇬🇧🎗️. All views are personal.
Newcastle-under-Lyme, England
Joined May 2011
- Tweets1.5K
- Following4K
- Followers589
- Likes5.5K
Matt Tabinor ن retweeted
Now online in @NDTsocial
Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design
🧐To advance nephrology research, we should embrace innovative study designs and methodologies.
▶️academic.oup.com/ndt/article…
Matt Tabinor ن retweeted
Drowning the kidneys:
from fluid overload to physiology-guided fluid management in onco-hematology
doi.org/10.1093/ckj/sfag232
Matt Tabinor ن retweeted
Mandatory weekend reading for nephrologists:
Disease modification in lupus nephritis
nature.com/articles/s41581-0…
By an SLE all-star ensemble:
@AKronbichler @Lupusreference @smirioglu @LuvacsL @AnnetteBruchfe1 @StefanieSteige6 @sarah_m_moran @OhioStateNeph @KateIsabelle24
Our #IWG @ERAkidney work on disease modification in lupus nephritis has just been published in #NRN
nature.com/articles/s41581-0…
@IoannisParodis @Lupusreference @smirioglu @LuvacsL @AnnetteBruchfe1 @StefanieSteige6 @sarah_m_moran @OhioStateNeph @KateIsabelle24 et al.
Matt Tabinor ن retweeted
Logistic Regression is the most important foundational algorithm in Classification Modeling.
In 2 minutes, I'll crush your confusion.
Let's dive in:
Matt Tabinor ن retweeted
Obesity pharmacotherapy is moving fast.
In our @bmj_latest NMA of 262 RCTs, tirzepatide & CagriSema produced the greatest weight loss, but benefits came with more adverse events. Few drugs showed CV benefits, and QoL did not meaningfully improve.
👉 bmj.com/content/394/bmj-2026…
Matt Tabinor ن retweeted
RAAS blockade in the kidney life-cycle: treatment standard
🔓doi.org/10.1093/ndt/gfag090
Matt Tabinor ن retweeted
🚨 New publication: AHA/ACC/ESC/WHF Expert Consensus on the Second Universal Definition of Heart Failure (2026) is out.
Honoured to be part of the writing group on this global effort. It moves us toward more nuanced, individualised HF care!
🔗ahajournals.org/doi/10.1161/…
Matt Tabinor ن retweeted
🥵As Europe faces extreme heat, protecting vulnerable patients has never been more important
Here are ten practical tips for caring for patients with CKD during extreme heat:
🌞doi.org/10.1093/ckj/sfae156
@ERAkidney
Matt Tabinor ن retweeted
ATENCIÓN 👀📢
¿Tienes dudas sobre si solicitar Albuminuria/Creatinuria o Proteinuria/Creatinuria?
Te recomiendo este artículo
doi.org/10.1093/ndt/gfag122
Matt Tabinor ن retweeted
Perspective suggests that technologies such as ultrasound guidance, plastic cannulas, simulation-based training, and augmented reality may improve cannulation success, reduce complications, and lessen pain and anxiety. Improvements and additional research needed. twp.ai/4hrb2Z #ASNCJASN
Matt Tabinor ن retweeted
A recent systematic review and meta-analysis offers the strongest evidence to date that SGLT2 inhibitors and GLP-1 receptor agonists improve survival and protect the allograft in individuals post-kidney transplant. Read a recap in #ASNKidneyNews: twp.ai/4hsCeH
Matt Tabinor ن retweeted
Whole-population trends in obesity across dimensions of
inequality in England, 2019–25: a retrospective, longitudinal
cohort study of 54 million adults
One of the largest ever studies led by @georgeinstitute’s @Fletcher_RA in @TheLancetEndo
Free link: sciencedirect.com/science/ar…
Matt Tabinor ن retweeted
Stacking the four-pillar approach for albuminuria reduction in CKD/diabetic kidney disease
combination therapy produces additive, near-doubling effects on albuminuria reduction vs. any single add-on — supporting a multi-pillar strategy in CKD
journals.lww.com/cjasn/abstr…
Matt Tabinor ن retweeted
Montoring for CMV infection after transplantation is important, but how often is often enough? New evidence posits that the first three months after preemptive therapy are the most important. Read more in #ASNKidneyNews: twp.ai/4hsCe1
Matt Tabinor ن retweeted
🔥 Published today, and just in time for summer conferences, here are your guidelines for presenting badly
Matt Tabinor ن retweeted
Pre-transplant and persistent post-transplant hyperparathyroidism and kidney transplant outcomes: a systematic review and meta-analysis
doi.org/10.1093/ckj/sfag205
Matt Tabinor ن retweeted
📹Watch Dr Daniel Kraus present the NDT publication:
Bleeding risk after kidney biopsy with platelet inhibition
👇👇👇
oup.cloud.panopto.eu/Panopto…
Matt Tabinor ن retweeted
ICYMI: The INFINITY trial found that finerenone reduced the risk of chronic kidney disease progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death.
Read now: spkl.io/601478eNC #ERA2026 @ERAKidney
ALT Figure showing cumulative incidence curves of efficacy outcomes estimated using Aalen\u2013Johansen methods accounting for mortality as a competing risk. Outcomes were assessed in time-to-event analyses. eGFR=estimated glomerular filtration rate. HR=hazard ratio. *The composite kidney outcome was a 57% or more decline in eGFR or kidney failure. \u2020Kidney failure was defined as sustained eGFR less than 15 mL/min per 1\u00B773 m\u00B2 or initiation of chronic dialysis or kidney transplantation. \u2021Comprises the composite kidney outcome, or heart failure hospitalisation or cardiovascular death. \u00A7Heart failure hospitalisation or cardiovascular death. Copyright:
